Condition
Relapsed/Refractory Multiple Myeloma(MM) clinical trials and research
Research outlook What's coming for Multiple myeloma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 2 Relapsed/Refractory Multiple Myeloma(MM) clinical trials that are recruiting, in China. By phase: Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 1Country
All recruiting trials (2)
-
Umbilical cord blood CAR-T cells targeting BCMA and CD19 for relapsed or refractory multiple myeloma
This trial will try an off-the-shelf CAR-T product made from umbilical cord blood that targets BCMA and CD19 in adults whose multiple myeloma has relapsed or stopped responding.
-
LCAR-F33S for relapsed or refractory multiple myeloma.
This trial will test an experimental LCAR-F33S cell infusion to see if it is safe and can shrink tumors in adults with relapsed or refractory multiple myeloma.
Related topics
Quick answers
How many Relapsed/Refractory Multiple Myeloma(MM) clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.